

3-(5-phenoxy-3-pyridyl)-3,7-diazabicyclo[3.3.1]nonane

$C_{18}H_{21}N_3O$

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 15:47:58 ON 30 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   29 AUG 2002  HIGHEST RN 445455-71-0
DICTIONARY FILE UPDATES:  29 AUG 2002  HIGHEST RN 445455-71-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d stat que l18

L6              STR
```



= ring bonds & nodes

```
                Ak @24

VAR G1=H/24
VAR G2=17/20
NODE ATTRIBUTES:
NSPEC   IS R      AT   7
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS R      AT  14
NSPEC   IS R      AT  15
CONNECT IS E1  RC AT  24
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  UNS  AT   4
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M3-X5 C  X3 N  AT   4

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE
L10             SCR 989 AND 1841 AND 1993 AND 1994 AND 2004
L16     2177222 SEA FILE=REGISTRY ABB=ON  C N/RELF(S)5-22/RATC(S)2/NRRS
```

L18 33 SEA FILE=REGISTRY SUB=L16 SSS FUL (L6 AND L10)

100.0% PROCESSED 215006 ITERATIONS 33 ANSWERS
SEARCH TIME: 00.00.19

```
=> fil capl; d que nos l19; fil uspatf; d que nos l20
FILE 'CAPLUS' ENTERED AT 15:48:14 ON 30 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 30 Aug 2002  VOL 137 ISS 10
FILE LAST UPDATED: 29 Aug 2002  (20020829/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.


L6              STR
L10             SCR 989 AND 1841 AND 1993 AND 1994 AND 2004
L16     2177222 SEA FILE=REGISTRY ABB=ON  C N/RELF(S)5-22/RATC(S)2/NRRS
L18          33 SEA FILE=REGISTRY SUB=L16 SSS FUL (L6 AND L10)
L19           7 SEA FILE=CAPLUS ABB=ON  L18


FILE 'USPATFULL' ENTERED AT 15:48:14 ON 30 AUG 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 29 Aug 2002 (20020829/PD)
FILE LAST UPDATED: 29 Aug 2002 (20020829/ED)
HIGHEST GRANTED PATENT NUMBER: US6442758
HIGHEST APPLICATION PUBLICATION NUMBER: US2002120971
CA INDEXING IS CURRENT THROUGH 29 Aug 2002 (20020829/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 29 Aug 2002 (20020829/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2002

>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US         <<<
>>>  publications, starting in 2001, for the inventions covered in     <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original     <<<
>>>  published document but also a list of any subsequent              <<<
>>>  publications.  The publication number, patent kind code, and      <<<
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                         <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together        <<<
```

```
>>>  through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from     <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.


L6              STR
L10             SCR 989 AND 1841 AND 1993 AND 1994 AND 2004
L16     2177222 SEA FILE=REGISTRY ABB=ON  C N/RELF(S)5-22/RATC(S)2/NRRS
L18          33 SEA FILE=REGISTRY SUB=L16 SSS FUL (L6 AND L10)
L20           8 SEA FILE=USPATFULL ABB=ON  L18


=> dup rem l19,l20
FILE 'CAPLUS' ENTERED AT 15:48:19 ON 30 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:48:19 ON 30 AUG 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L19
PROCESSING COMPLETED FOR L20
L30          13 DUP REM L19 L20 (2 DUPLICATES REMOVED)
                ANSWERS '1-7' FROM FILE CAPLUS
                ANSWERS '8-13' FROM FILE USPATFULL

=> d ibib abs hitstr 1-13 l30; fil cao; d que nos l21; fil hom

L30  ANSWER 1 OF 13  CAPLUS  COPYRIGHT 2002 ACS        DUPLICATE 1
ACCESSION NUMBER:         2002:90615  CAPLUS
DOCUMENT NUMBER:          136:134798
TITLE:                    Preparation of N-aryl diazabicyclic compounds for
                          treatment of central nervous system disorders
INVENTOR(S):              Miller, Craig Harrison; Dull, Gary Maurice; Miao, Lan;
                          Lynm, Dwo; Schmitt, Jeffrey Daniel; Clark, Thomas
                          Jeffrey
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S.
                          Ser. No. 578,768.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     US 2002013309      A1   20020131       US 2001-864905   20010524
     US 6440970         B1   20020827       US 2000-578768   20000525
     WO 2001090109      A1   20011129       WO 2001-US16941  20010524
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
```

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2000-578768 A2 20000525
US 2001-864905 A 20010524
OTHER SOURCE(S): MARPAT 136:134798
GI



AB The present invention relates to the prepn. of N-aryl diazabicyclic compds. I [wherein Q = (CH2)u; Q1 = (CH2)v, Q2 = (CH2)w; Q3 = (CH2)x, and Q4 = (CH2)y; u, v, w, x = independently 0-4; Y = 1 or 2; Z = a non-hydrogen substituent having a sigma m value between -0.3 and about 0.75; n = 0-10; R = H or alkyl; Cy = (un)substituted Ph, pyridyl, pyrimidinyl, pyrazinyl, or 1,2,4-triazinyl] and their use in the treatment of central nervous system disorders. Of particular interest are 2-pyridyl diazabicyclic compds., such as (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane (II) ,(1S,4S)-2-(5-(4-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(3,4-dimethoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-fluorophenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, and (1S,4S)-2-(5-benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane. The present invention also relates to prodrug derivs. of the compds. of the present invention. For example, coupling of 3-bromo-5-(4-methoxyphenoxy)pyridine (prepn. given) with (1S,4S)-N-(tert-butoxycarbonyl)-2,5-diazabicyclo[2.2.1]heptane in the presence of tris(dibenzylideneacetone)dipalladium and (rac)-2,2-bis(diphenylphosphino)-1,1-binaphthyl, and NaOBu-t in toluene, followed by deprotection using TFA and salt formation, afforded II.bul.hemigalactarate. The latter exhibited a Ki of 13 nM in binding studies with certain CNS nicotinic receptors.

IT **374934-99-3P**, (1S,4S)-2-[5-(4-Methoxyphenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane **374935-02-1P**, (1S,4S)-2-[5-(3-Methoxyphenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(nicotinic receptor ligand; prepn. of N-aryl diazabicyclic compds. as nicotinic receptor ligands for treatment of central nervous system disorders)

RN 374934-99-3 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(4-methoxyphenoxy)-3-pyridinyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



514/349
514/249

RN 374935-02-1 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(3-methoxyphenoxy)-3-pyridinyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **374935-09-8P**, (1S,4S)-2-[5-(4-Fluorophenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane dihydrochloride **374935-11-2P**, (1S,4S)-2-(5-Benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane dihydrochloride **392661-65-3P** **392661-67-5P** **392661-68-6P**, (1S,4S)-2-[5-(4-Fluorophenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane **392661-69-7P**, (1S,4S)-2-(5-Benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nicotinic receptor ligand; prepn. of N-aryl diazabicyclic compds. as nicotinic receptor ligands for treatment of central nervous system disorders)
RN 374935-09-8 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(4-fluorophenoxy)-3-pyridinyl]-, dihydrochloride, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



2 HCl

RN 374935-11-2 CAPLUS
CN Methanone, [5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-pyridinyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 392661-65-3 CAPLUS
CN Galactaric acid, compd. with (1S,4S)-2-[5-(4-methoxyphenoxy)-3-pyridinyl]-2,5-diazabicyclo[2.2.1]heptane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 374934-99-3
CMF C17 H19 N3 O2

Absolute stereochemistry.



CM 2

CRN 526-99-8
CMF C6 H10 O8
CDES 5:GALACTO

Relative stereochemistry.



RN 392661-67-5 CAPLUS
CN Galactaric acid, compd. with (1S,4S)-2-[5-(3-methoxyphenoxy)-3-pyridinyl]-2,5-diazabicyclo[2.2.1]heptane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 374935-02-1
CMF C17 H19 N3 O2

Absolute stereochemistry.



CM 2

CRN 526-99-8
CMF C6 H10 O8
CDES 5:GALACTO

Relative stereochemistry.



RN 392661-68-6 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(4-fluorophenoxy)-3-pyridinyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392661-69-7 CAPLUS
CN Methanone, [5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-pyridinyl]phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L30 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2
ACCESSION NUMBER: 1999:818934 CAPLUS
DOCUMENT NUMBER: 132:44977

TITLE: Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anticoagulants
INVENTOR(S): Kochanny, Monica; Morrissey, Michael M.; Ng, Howard P.
PATENT ASSIGNEE(S): Berlex Laboratories, Inc., USA
SOURCE: U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 713,066.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6008234	A	19991228	US 1997-920319	19970827
WO 9811094	A1	19980319	WO 1997-EP4961	19970911
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9743843	A1	19980402	AU 1997-43843	19970911
AU 723999	B2	20000907		
EP 929547	A1	19990721	EP 1997-942015	19970911
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1234798	A	19991110	CN 1997-198664	19970911
JP 2001500147	T2	20010109	JP 1998-513257	19970911
KR 2000036017	A	20000626	KR 1999-701989	19990310
NO 9901206	A	19990511	NO 1999-1206	19990311
US 6177473	B1	20010123	US 1999-439065	19991112
US 6232325	B1	20010515	US 1999-438354	19991112
US 6265404	B1	20010724	US 1999-438270	19991112
CN 1338454	A	20020306	CN 2001-121736	20010703

PRIORITY APPLN. INFO.: US 1996-713066 A2 19960912
US 1997-920319 A 19970827
WO 1997-EP4961 W 19970911

OTHER SOURCE(S): MARPAT 132:44977

AB Benzamidine derivs. substituted by cyclic amino acid and cyclic hydroxy acid derivs. are provided which are useful as anticoagulants. Also disclosed are pharmaceutical compns. contg. the compds. of the invention, and methods of using the compds. to treat disease-states characterized by thrombotic activity.

IT **204768-46-7 204768-48-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzamidine deriv. prepn. for anticoagulants)

RN 204768-46-7 CAPLUS

CN 2-Azabicyclo[2.2.1]heptane-6-carboxylic acid, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 204768-48-9 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:31453 CAPLUS
DOCUMENT NUMBER: 136:85836
TITLE: Aryl- and heteroaryl-substituted diazabicycloalkanes as cholinergic ligands for the nicotinic acetylcholine receptor
INVENTOR(S): Peters, Dan; Olsen, Gunnar M.; Nielsen, Elsebet Ostergaard; Ahring, Philip K.; Nielsen, Simon Feldbaek; Jorgensen, Tino Dyhring
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002002564 A1 20020110 WO 2001-DK432 20010620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2001065831 A5 20020114 AU 2001-65831 20010620
PRIORITY APPLN. INFO.: DK 2000-1037 A 20000704
WO 2001-DK432 W 20010620
OTHER SOURCE(S): MARPAT 136:85836
GI



I

AB Title compds. I [one of R and R1 = H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, monocyclic or polycyclic aryl, aralkyl and the other = 1 (un)substituted monocyclic or polycyclic aryl; n = 2, 3; m = 1, 2, 3] and their dimers were prepd. for use as cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Thus, 9-methyl-3,9-diazabicyclo[4.2.1]nonane was treated with 2-chloroquinoline to give the 3-(2-quinolinyl) deriv. which had an IC50 for inhibition of noradrenaline uptake at rat brain serotonin transporters of 0.013 .mu.M. Due to their pharmacol. profile I may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chem. substances.

IT **387870-75-9P 387870-76-0P 387870-77-1P**
387870-78-2P 387870-79-3P 387870-80-6P
387870-81-7P 387870-82-8P 387870-83-9P
387870-84-0P 387870-85-1P 387870-86-2P
387870-87-3P 387870-88-4P 387870-89-5P
387870-90-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl- and heteroaryl-substituted diazabicycloalkanes as cholinergic ligands for the nicotinic acetylcholine receptor)

RN 387870-75-9 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(6-phenoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 387870-76-0 CAPLUS
CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(6-phenoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 387870-77-1 CAPLUS
CN 3,10-Diazabicyclo[4.3.1]decane, 3-(6-phenoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 387870-78-2 CAPLUS
CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(6-phenoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 387870-79-3 CAPLUS
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[6-(2-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-80-6 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[6-(2-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-81-7 CAPLUS
CN 3,10-Diazabicyclo[4.3.1]decane, 3-[6-(2-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-82-8 CAPLUS
CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-[6-(2-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-83-9 CAPLUS
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[6-(3-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-84-0 CAPLUS
CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[6-(3-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-85-1 CAPLUS
CN 3,10-Diazabicyclo[4.3.1]decane, 3-[6-(3-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-86-2 CAPLUS
CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-[6-(3-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-87-3 CAPLUS
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[6-(4-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-88-4 CAPLUS
CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[6-(4-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-89-5 CAPLUS
CN 3,10-Diazabicyclo[4.3.1]decane, 3-[6-(4-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 387870-90-8 CAPLUS
CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-[6-(4-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:868455 CAPLUS
DOCUMENT NUMBER: 136:6011
TITLE: Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
INVENTOR(S): Miller, Craig Harrison; Dull, Gary Maurice; Miao, Lan; Lynm, Dwo; Schmitt, Jeffrey Daniel; Clark, Thomas Jeffrey
PATENT ASSIGNEE(S): Targacept, Inc., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090109	A1	20011129	WO 2001-US16941	20010524

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6440970 B1 20020827 US 2000-578768 20000525
US 2002013309 A1 20020131 US 2001-864905 20010524
PRIORITY APPLN. INFO.: US 2000-578768 A 20000525
US 2001-864905 A 20010524
OTHER SOURCE(S): MARPAT 136:6011

AB The present invention relates to diazabicyclic compds., preferably to N-aryl diazabicyclic compds. Of particular interest are 2-pyridyl diazabicyclic compds., such as (1S,4S)-2-[5-(3-methoxyphenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane. Other exemplary compds. of the present invention include: (1S,4S)-2-[5-(4-methoxyphenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane (I), (1S,4S)-2-[5-(3,4-dimethoxyphenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-[5-(4-fluorophenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane, and (1S,4S)-2-[5-benzoyl-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane. Thus, I hemigalactarate was prepd. in 4 steps starting from 4-methoxyphenol and 3,5-dibromopyridine. A binding const. of 13 nM was detd. for I hemigalactarate, showing high-affinity binding to certain CNS nicotinic receptors.

IT **374935-07-6P 374935-08-7P 374935-09-8P**
374935-11-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands)

RN 374935-07-6 CAPLUS

CN Galactaric acid, compd. with (1S,4S)-2-[5-(4-methoxyphenoxy)-3-pyridinyl]-2,5-diazabicyclo[2.2.1]heptane (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 374934-99-3
CMF C17 H19 N3 O2

Absolute stereochemistry.



CM 2

CRN 526-99-8
CMF C6 H10 O8
CDES 5:GALACTO

Relative stereochemistry.



RN 374935-08-7 CAPLUS
CN Galactaric acid, compd. with (1S,4S)-2-[5-(3-methoxyphenoxy)-3-pyridinyl]-2,5-diazabicyclo[2.2.1]heptane (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 374935-02-1
CMF C17 H19 N3 O2

Absolute stereochemistry.



CM 2

CRN 526-99-8
CMF C6 H10 O8
CDES 5:GALACTO

Relative stereochemistry.



RN 374935-09-8 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(4-fluorophenoxy)-3-pyridinyl]-, dihydrochloride, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



2 HCl

RN 374935-11-2 CAPLUS
CN Methanone, [5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-pyridinyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



2 HCl

IT **374934-99-3P**, (1S,4S)-2-(5-(4-Methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane **374935-02-1P**, (1S,4S)-2-(5-(3-Methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands)
RN 374934-99-3 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(4-methoxyphenoxy)-3-pyridinyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 374935-02-1 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(3-methoxyphenoxy)-3-pyridinyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:180867 CAPLUS
DOCUMENT NUMBER: 128:230376
TITLE: Benzamidine derivatives substituted by cyclic amino acid or cyclic hydroxy acid derivatives, and their use as anticoagulants
INVENTOR(S): Kochanny, Monica; Morrissey, Michael M.; Ng, Howard P.
PATENT ASSIGNEE(S): Schering A.-G., Germany
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9811094	A1	19980319	WO 1997-EP4961	19970911

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,
VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG

US 6008234	A	19991228	US 1997-920319	19970827
AU 9743843	A1	19980402	AU 1997-43843	19970911
AU 723999	B2	20000907		
EP 929547	A1	19990721	EP 1997-942015	19970911
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001500147	T2	20010109	JP 1998-513257	19970911
NO 9901206	A	19990511	NO 1999-1206	19990311

PRIORITY APPLN. INFO.: US 1996-713066 A 19960912
US 1997-920319 A 19970827
WO 1997-EP4961 W 19970911

OTHER SOURCE(S): MARPAT 128:230376

GI



I



II

AB The invention is directed to benzamidine derivs. substituted by cyclic amino acid and cyclic hydroxy acid derivs., which are represented by seven general formulas, e.g., I [A = CR8 or N; Z1, Z2 = O, NR9, S, S(O), S(O)2, or OCH2; R1, R4 = H, halo, alkyl, NO2, OR9, CO2R9, NR9R10 or derivs.; R2 = C(:NH)NH2, C(:NH)NHOR9, C(:NH)NHCO2R12, C(:NH)NHCOR9, etc.; R3 = H, alkyl, halo, haloalkyl, NO2, ureido, guanidino, OR9, C(:NH)NH2 or derivs., etc.; R5, R6 = H, halo, alkyl, haloalkyl, NR9R10, CO2R9, etc.; R7 = NR9(CR9R10)0-4R13, O(CR9R10)0-4R13, or NR14R15; R8 = H, alkyl, halo; R9, R10 = H, alkyl, (un)substituted aryl or aralkyl; R12 = alkyl, (un)substituted aryl or aralkyl; R13 = (un)substituted carbocycle; R13, NR14R15 = (un)substituted heterocycle]. The compds. are useful as anticoagulants. This invention is also directed to pharmaceutical compns. contg. the compds., and their use to treat thrombotic disease states. For example, pentafluoropyridine underwent a sequence of: (1) amination in the 4-position by Et 1-amino-1-cyclopentanecarboxylate-HCl (82%); (2) N-methylation of the amino group (65%); (3) etherification in the 2-position with 2-(benzyloxy)-5-cyanophenol (60%); (4) etherification in the 6-position with 3-(1-methylimidazolin-2-yl)phenol; and (5) Pinner

reaction of the nitrile with concomitant debenzylation, to give title compd. II (isolated as the CF3CO2H salt).

IT **204768-46-7P 204768-48-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzamidine derivs. as anticoagulants)

RN 204768-46-7 CAPLUS
CN 2-Azabicyclo[2.2.1]heptane-6-carboxylic acid, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 204768-48-9 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



L30 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1996:685153 CAPLUS
DOCUMENT NUMBER:	125:328725
TITLE:	Preparation of heterocyclic compounds as antitumor agents
INVENTOR(S):	Aono, Tetsuya; Marui, Shogo; Itoh, Fumio; Yamaoka, Masuo; Nakao, Masafumi
PATENT ASSIGNEE(S):	Takeda Chemical Industries, Ltd., Japan
SOURCE:	Eur. Pat. Appl., 145 pp.

Searched by Barb O'Bryen, STIC 308-4291

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733633	A1	19960925	EP 1996-104176	19960315
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5753664	A	19980519	US 1996-614893	19960313
CA 2171932	AA	19960917	CA 1996-2171932	19960315
JP 09095485	A2	19970408	JP 1996-59508	19960315

PRIORITY APPLN. INFO.: JP 1995-56869 19950316
JP 1995-191770 19950727
OTHER SOURCE(S): MARPAT 125:328725
GI



II

AB RZZ1COR2 [I; R = (un)substituted condensed pyrimidinone or condensed pyridazinone ring (sic); R2 cyclic group; Z = divalent group; Z1 = divalent cyclic group] were prepd. Thus, 2-mercapto-3-methyl-4(3H)-quinazolinone was etherified by 4-ClC6H4COC6H4(CH2Br)-4 to give title compd. II. Data for in vivo antitumor activity of selected I were given.

IT **183168-70-9P 183168-80-1P 183169-03-1P**
183170-11-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic compds. as antitumor agents)

RN 183168-70-9 CAPLUS
CN 1H-Purine-2,6-dione, 7-[[4-[(6-[1,4'-bipiperidin]-1'-yl-3-pyridinyl)carbonyl]phenyl]methyl]-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 183168-80-1 CAPLUS
CN 4(3H)-Quinazolinone, 3,5-dimethyl-2-[[[4-[[6-[4-(1-piperidinyl)-1-

piperazinyl]-3-pyridinyl]carbonyl]phenyl]methyl]thio]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 183169-03-1 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-5-[[4-[[6-(1-piperidinyl)-3-pyridinyl]carbonyl]phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 183170-11-8 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[[4-[(6-[1,4'-bipiperidin]-1'-yl-3-pyridinyl)carbonyl]phenyl]methyl]-3-ethyl-3,7-dihydro-5-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L30 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:181550 CAPLUS
DOCUMENT NUMBER: 124:232495
TITLE: preparation of thienylazole and thienotriazolodiazepine compounds as cholecystokinin

Searched by Barb O'Bryen, STIC 308-4291

antagonists

INVENTOR(S): Kitajima, Hiroshi; Ehara, Syuji; Sato, Hideaki; Moriwaki, Minoru; Onishi, Kenichi

PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9532963	A1	19951207	WO 1994-JP889	19940601
W: JP				
WO 9532964	A1	19951207	WO 1995-JP1071	19950601
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2191756	AA	19951207	CA 1995-2191756	19950601
EP 776892	A1	19970604	EP 1995-920233	19950601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5760032	A	19980602	US 1996-750025	19961122

PRIORITY APPLN. INFO.: JP 1994-889 19940601
WO 1994-JP889 19940601
WO 1995-JP1071 19950601

OTHER SOURCE(S): MARPAT 124:232495

GI



I



II



III

AB The title compds. [I, II; R1, R2 = H, halo, C1-5 alkyl, etc.; AB = N=N, etc; R3, R19 = H, C1-5 alkyl, etc.; Y = NHCO, NHCONH, NHCO2, etc.; Z1, Z2 = aryl, heteroaryl, etc.; Ar = halophenyl, etc.; m = 0-5], useful in preventing and treating central and peripheral nerve diseases such as anxiety and schizophrenia and digestive diseases such as pancreatitis and gastrointestinal ulcer, are prepd. PhCOCl and Et3N were added to a soln. of amino compd. III (R = H) in DMF under cooling and the soln. stirred at

room temp. to give amide III (R = PhCO). I and II are effective at 0.1-50 mg.

IT **174666-66-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thienylazole and thienotriazolodiazepine compds. as cholecystokinin antagonists)

RN 174666-66-1 CAPLUS

CN 1H-Indole-2-carboxamide, N-[[4-[3-(2-chlorobenzoyl)-5-ethyl-2-thienyl]-5-cyclohexyl-4H-1,2,4-triazol-3-yl]methyl]- (9CI) (CA INDEX NAME)



L30 ANSWER 8 OF 13 USPATFULL

ACCESSION NUMBER:	2002:217266 USPATFULL
TITLE:	Pharmaceutical compositions and methods for use
INVENTOR(S):	Clark, Thomas Jeffrey, High Point, NC, United States Dull, Gary Maurice, Lewisville, NC, United States Lynm, Dwo, Winston-Salem, NC, United States Miao, Lan, Winston-Salem, NC, United States Miller, Craig Harrison, Winston-Salem, NC, United States Schmitt, Jeffrey Daniel, Winston-Salem, NC, United States
PATENT ASSIGNEE(S):	Targacept, Inc., Winston-Salem, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6440970	B1	20020827	
APPLICATION INFO.:	US 2000-578768		20000525	(9)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Shah, Mukund J.
ASSISTANT EXAMINER:	Liu, Hong
LEGAL REPRESENTATIVE:	Womble Carlyle Sandridge & Rice, PLLC
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	1439

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to diazabicyclic compounds, and preferably N-aryl diazabicyclic compounds. Of particular interest are 2-pyridyl diazabicyclic compounds, such as (1S,4S)-2-(3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane. Other exemplary compounds of the present invention include: (1S,4S)-2-(5-(4-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-pyrimidinyl)-2,5-diazabicyclo[2.2.1]heptane and (1S,4S)-2-(6-chloro-3-pyridazinyl)-2,5-diazabicyclo[2.2.1]heptane. The present invention also relates to prodrug derivatives of the compounds of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **374934-99-3P**, (1S,4S)-2-[5-(4-Methoxyphenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane **374935-02-1P**, (1S,4S)-2-[5-(3-Methoxyphenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane
(nicotinic receptor ligand; prepn. of N-aryl diazabicyclic compds. as nicotinic receptor ligands for treatment of central nervous system disorders)

RN 374934-99-3 USPATFULL

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(4-methoxyphenoxy)-3-pyridinyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 374935-02-1 USPATFULL

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(3-methoxyphenoxy)-3-pyridinyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **374935-09-8P**, (1S,4S)-2-[5-(4-Fluorophenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane dihydrochloride **374935-11-2P**, (1S,4S)-2-(5-Benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane dihydrochloride **392661-65-3P 392661-67-5P 392661-68-6P**, (1S,4S)-2-[5-(4-Fluorophenoxy)-3-pyridyl]-2,5-diazabicyclo[2.2.1]heptane **392661-69-7P**, (1S,4S)-2-(5-Benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane
(nicotinic receptor ligand; prepn. of N-aryl diazabicyclic compds. as nicotinic receptor ligands for treatment of central nervous system disorders)

RN 374935-09-8 USPATFULL
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(4-fluorophenoxy)-3-pyridinyl]-, dihydrochloride, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



2 HCl

RN 374935-11-2 USPATFULL
CN Methanone, [5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-pyridinyl]phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



2 HCl

RN 392661-65-3 USPATFULL
CN Galactaric acid, compd. with (1S,4S)-2-[5-(4-methoxyphenoxy)-3-pyridinyl]-2,5-diazabicyclo[2.2.1]heptane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 374934-99-3
CMF C17 H19 N3 O2

Absolute stereochemistry.



CM 2

CRN 526-99-8
CMF C6 H10 O8
CDES 5:GALACTO

Relative stereochemistry.



RN 392661-67-5 USPATFULL
CN Galactaric acid, compd. with (1S,4S)-2-[5-(3-methoxyphenoxy)-3-pyridinyl]-2,5-diazabicyclo[2.2.1]heptane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 374935-02-1
CMF C17 H19 N3 O2

Absolute stereochemistry.



CM 2

CRN 526-99-8
CMF C6 H10 O8
CDES 5:GALACTO

Relative stereochemistry.



RN 392661-68-6 USPATFULL
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[5-(4-fluorophenoxy)-3-pyridinyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392661-69-7 USPATFULL
CN Methanone, [5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-pyridinyl]phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L30 ANSWER 9 OF 13 USPATFULL
ACCESSION NUMBER: 2001:117010 USPATFULL
TITLE: Benzamidine derivatives substituted by cyclic amino

	acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
INVENTOR(S):	Kochanny, Monica, San Rafael, CA, United States Morrissey, Michael M., Danville, CA, United States Ng, Howard P., El Sobrante, CA, United States
PATENT ASSIGNEE(S):	Berlex Laboratories, Inc., Richmond, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6265404	B1	20010724
APPLICATION INFO.:	US 1999-438270		19991112 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-920319, filed on 27 Aug 1997, now patented, Pat. No. US 6008234
Continuation-in-part of Ser. No. US 1996-713066, filed on 12 Sep 1996, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Shah, Mukund J.
ASSISTANT EXAMINER:	Truong, Tamthom N.
LEGAL REPRESENTATIVE:	Roth, Carol J.
NUMBER OF CLAIMS:	3
EXEMPLARY CLAIM:	1
LINE COUNT:	2720

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **204768-46-7P 204768-48-9P**
(prepn. of benzamidine derivs. as anticoagulants)

RN 204768-46-7 USPATFULL

CN 2-Azabicyclo[2.2.1]heptane-6-carboxylic acid, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 204768-48-9 USPATFULL

CN 3-Isoquinolinecarboxylic acid, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



L30 ANSWER 10 OF 13 USPATFULL
ACCESSION NUMBER: 2001:71560 USPATFULL
TITLE: Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatves and their use as anti-coagulants
INVENTOR(S): Kochanny, Monica, San Rafael, CA, United States
Morrissey, Michael M., Danville, CA, United States
Ng, Howard P., El Sobrante, CA, United States
PATENT ASSIGNEE(S): Berlex Laboratories, Inc., Richmond, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6232325	B1	20010515
APPLICATION INFO.:	US 1999-438354		19991112 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-920319, filed on 27 Aug 1997, now patented, Pat. No. US 6008234
Continuation-in-part of Ser. No. US 1996-713066, filed on 12 Sep 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Trouang, Tamthom N.
LEGAL REPRESENTATIVE: Roth, Carol J.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 2733
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **204768-46-7P 204768-48-9P**
(prepn. of benzamidine derivs. as anticoagulants)
RN 204768-46-7 USPATFULL
CN 2-Azabicyclo[2.2.1]heptane-6-carboxylic acid, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 204768-48-9 USPATFULL
CN 3-Isoquinolinecarboxylic acid, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



L30 ANSWER 11 OF 13 USPATFULL
ACCESSION NUMBER: 2001:10935 USPATFULL
TITLE: Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
INVENTOR(S): Kochanny, Monica, San Rafael, CA, United States
Morrissey, Michael M., Danville, CA, United States
Ng, Howard P., El Sobrante, CA, United States
PATENT ASSIGNEE(S): Berlex Laboratories, Inc., Richmond, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6177473	B1	20010123
APPLICATION INFO.:	US 1999-439065		19991112 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-920319, filed on 27 Aug 1997, now patented, Pat. No. US 6008234
Continuation-in-part of Ser. No. US 1996-713066, filed on 12 Sep 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.

Searched by Barb O'Bryen, STIC 308-4291

ASSISTANT EXAMINER: Truong, Tamthom N.
LEGAL REPRESENTATIVE: Roth, Carol J.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 2734
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **204768-46-7P 204768-48-9P**
(prepn. of benzamidine derivs. as anticoagulants)
RN 204768-46-7 USPATFULL
CN 2-Azabicyclo[2.2.1]heptane-6-carboxylic acid, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 204768-48-9 USPATFULL
CN 3-Isoquinolinecarboxylic acid, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



L30 ANSWER 12 OF 13 USPATFULL
ACCESSION NUMBER: 1998:61647 USPATFULL
TITLE: Thienylazole compound and thienotriazolodiazepine compound
INVENTOR(S): Kitajima, Hiroshi, Fukuoka, Japan
Ehara, Syuji, Fukuoka, Japan
Sato, Hideaki, Fukuoka, Japan
Moriwaki, Minoru, Osaka, Japan
Onishi, Kenichi, Fukuoka, Japan
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5760032		19980602	
	WO 9532964		19951207	
APPLICATION INFO.:	US 1996-750025		19961122	(8)
	WO 1995-JP1071		19950601	
			19961122	PCT 371 date
			19961122	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-889	19940601

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 8298
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Thienylazole compounds (I) and thienotriazolodiazepine compounds (II) of the formulas ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen, halogen, C.sub.1 -C.sub.5 alkyl and the like; --A.dbd.B-- is --N.dbd.N-- and the like; R.sup.3 and R.sup.19 are hydrogen, C.sub.1 -C.sub.5 alkyl and the like; Y is --NHCO--, --NHCONH--, --NHCOO-- and the like; Z.sup.1 and Z.sup.2 are aryl, heteroaryl and the like; Ar is halogen-substituted phenyl and the like; and m is 0 or an integer of 1-5.

The compounds of the present invention have CCK antagonistic action and gastrin antagonistic action, particularly potent antagonistic action against CCK-A receptor, and are useful as agents for the prophylaxis and treatment of central and peripheral nervous system diseases (e.g., anxiety, schizophrenia, and the like) and digestive diseases (e.g., pancreatitis, gastric ulcer, enterelcosis, irritable bowel syndrome, constipation, and the like).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **174666-66-1P**
(prepn. of thienylazole and thienotriazolodiazepine compds. as cholecystokinin antagonists)
RN 174666-66-1 USPATFULL
CN 1H-Indole-2-carboxamide, N-[[4-[3-(2-chlorobenzoyl)-5-ethyl-2-thienyl]-5-cyclohexyl-4H-1,2,4-triazol-3-yl]methyl]- (9CI) (CA INDEX NAME)



L30 ANSWER 13 OF 13 USPATFULL
ACCESSION NUMBER: 1998:54907 USPATFULL
TITLE: Heterocyclic compounds, their production and use
INVENTOR(S): Aono, Tetsuya, Kyoto, Japan
Marui, Shogo, Hyogo, Japan
Itoh, Fumio, Osaka, Japan
Yamaoka, Masuo, Hyogo, Japan
Nakao, Masafumi, Nara, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5753664		19980519	
APPLICATION INFO.:	US 1996-614893		19960313	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-56869	19950316
	JP 1995-191770	19950727

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Grumbling, Matthew V.
LEGAL REPRESENTATIVE: Fitzpatrick, Cella, Harper & Scinto
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 8800
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel compound of the formula:

A--Z--Ar.sup.1 1'CO--Ar.sup.2

wherein A is a condensed pyrimidinone or condensed pyridazinone ring; Ar.sup.1 and Ar.sup.2 are independently a ring; Z is a divalent group, or a salt thereof which have an excellent antitumor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **183168-70-9P 183168-80-1P 183169-03-1P**
183170-11-8P
(prepn. of heterocyclic compds. as antitumor agents)
RN 183168-70-9 USPATFULL
CN 1H-Purine-2,6-dione, 7-[[4-[(6-[1,4'-bipiperidin]-1'-yl-3-pyridinyl)carbonyl]phenyl]methyl]-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 183168-80-1 USPATFULL
CN 4(3H)-Quinazolinone, 3,5-dimethyl-2-[[[4-[[6-[4-(1-piperidinyl)-1-piperazinyl]-3-pyridinyl]carbonyl]phenyl]methyl]thio]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 183169-03-1 USPATFULL
CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 1,3-dimethyl-5-[[4-[[6-(1-piperidinyl)-3-pyridinyl]carbonyl]phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 183170-11-8 USPATFULL
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[[4-[(6-[1,4'-bipiperidin]-1'-yl-3-pyridinyl)carbonyl]phenyl]methyl]-3-ethyl-3,7-dihydro-5-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

FILE 'CAOLD' ENTERED AT 15:48:46 ON 30 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L6		STR
L10		SCR 989 AND 1841 AND 1993 AND 1994 AND 2004
L16	2177222	SEA FILE=REGISTRY ABB=ON C N/RELF(S)5-22/RATC(S)2/NRRS
L18	33	SEA FILE=REGISTRY SUB=L16 SSS FUL (L6 AND L10)
L21	0	SEA FILE=CAOLD ABB=ON L18

FILE 'HOME' ENTERED AT 15:48:46 ON 30 AUG 2002